Explainer · 14 Nov 2026 · 7 min
Retatrutide explained: the triple agonist everyone is talking about
What it is, how it differs from earlier GLP-1 peptides, and where the research stands right now.
Retatrutide is an investigational peptide that acts on three hormone receptors at once: GLP-1, GIP and glucagon. Earlier compounds targeted one or two of these.
Interest exploded after phase 2 results were published, showing larger effects on body weight in study participants than earlier single-target compounds. Phase 3 trials are ongoing.
Important: retatrutide is not an approved medicine. Research-grade material is sold for laboratory research only.
Exclusive for PeptideNews readers
Get exclusive access to a trusted source of RUO peptides
As a research site, we can give you access to a supplier that meets the standards we write about.
- 60-day money-back guarantee
- Temperature-protected shipping
- Produced in the EU
- Third-party lab tested
- Traceable testing
- 99% purity
- Delivery in 2–5 days across the EU
For research use only (RUO). Not for human consumption.